A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study - Trial NCT03710252
Access comprehensive clinical trial information for NCT03710252 through Pure Global AI's free database. This Phase 4 trial is sponsored by American Research Corporation and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
American Research Corporation
Timeline & Enrollment
Phase 4
Mar 01, 2016
Sep 01, 2017
Primary Outcome
The primary analysis will be sustained virologic response 12 weeks after the last treatment dose (SVR12) for the all treated population.
Summary
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24
 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03710252
Non-Device Trial